tDCS for Cognitive Impairment Associated With Recent-onset Schizophrenia (STICOG)

Efficacy and Auditory Biomarker Analysis of Fronto-Temporal Transcranial Direct Current Stimulation (tDCS) in Targeting Cognitive Impairment Associated With Recent-onset Schizophrenia: A Randomized Double-blind Sham-controlled Trial

Background: In parallel to the traditional symptomatology, deficits in cognition (memory, attention, reasoning, social functioning) contribute significantly to disability and suffering in individuals with schizophrenia. Cognitive deficits have been closely linked to alterations in early auditory processes (EAP) that occur in auditory cortical areas. Preliminary evidence indicates that cognitive deficits in schizophrenia can be improved with a reliable and safe non-invasive brain stimulation technique called tDCS (transcranial Direct Current Stimulation). However, a significant proportion of patients derive no cognitive benefits after tDCS treatment. Further, the neurobiological mechanisms of cognitive changes after tDCS have been poorly explored in trials and are thus still unclear.

Method: The study is designed as a randomized, double-blind, 2-arm parallel-group, sham controlled, 4-centers trial. Sixty participants with recent-onset schizophrenia and cognitive impairment will be randomly allocated to receive either active (n=30) or sham (n=30) tDCS (20-min, 2-mA, 10 sessions during 5 consecutive weekdays). The anode will be placed over the left dorsolateral prefrontal cortex and the cathode over the left auditory cortex. Cognition, tolerance, symptoms, general outcome and EAP (measured with EEG and multimodal MRI) will be assessed prior to tDCS (baseline), after the 10 sessions, and at 1- and 3-month follow-up. The primary outcome will be the number of responders, defined as participants demonstrating a cognitive improvement ≥Z=0.5 from baseline on the MATRICS Consensus Cognitive Battery total score at 1-month follow-up. Additionally, we will measure how differences in EAP modulate individual cognitive benefits from active tDCS and whether there are changes in EAP measures in responders after active tDCS.

Discussion: Besides proposing a new fronto-temporal tDCS protocol by targeting the auditory cortical areas, we aim to conduct an RCT with follow-up assessments up to 3-months and a large sample size. In addition, this study will allow identifying and assessing the value of a wide range of neurobiological EAP measures for predicting and explaining cognitive deficits improvement after tDCS. The results of this trial will constitute a step toward the use of tDCS as a therapeutic tool for the treatment of cognitive impairment in recent-onset schizophrenia.

Study Overview

• Status: Not yet recruiting
• Conditions: Schizophrenia; Psychotic Disorder
• Intervention / Treatment: Device: left fronto-temporal transcranial Direct Current Stimulation (tDCS)

• Study Type: Interventional
• Enrollment (Anticipated): 60
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Bron, France, 69500
    • CH Le Vinatier
  • Saint-Étienne, France, 42055
    • CHU Saint-Etienne
  • Auvergne-Rhône-Alpes
    • La Tronche, Auvergne-Rhône-Alpes, France, 38700
      • Chu Grenoble Alpes
  • Rhône-Alpes
    • Saint-Égrève, Rhône-Alpes, France, 38120
      • CH Alpes-Isère

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 35 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

The inclusion criteria include:

1. subjects of both genders, diagnosed with recent-onset schizophrenia (first 3 years of illness), confirmed through the Structured Clinical Interview for the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 5th edition (SCID-5);
2. aged 18-35 years;
3. intelligence quotient (IQ) > 55;
4. cognitive deficit confirmed by a MCCB (MATRICS Cognitive Consensus Battery) total score T-score < 40;
5. the subjects should be receiving stable doses of antipsychotics for ≥ 4 weeks;
6. the subjects are covered by a public health insurance.

The exclusion criteria include:

1. pregnant (controlled by urine pregnancy test in females of childbearing age) or breastfeeding women;
2. unstable or acute medical conditions;
3. subjects who receive involuntary treatment or guardianship;
4. history of cranioencephalic trauma with loss of consciousness or central nervous system diseases that affect the brain;
5. use of drugs that affect cognitive performance such as anticholinergic agents and benzodiazepines;
6. current diagnosis of substance abuse or history of substance dependence in the last 6 months, except nicotine;
7. MRI (Magnetic Resonance Imaging), PET (Positron Emission Tomography) or tDCS (transcranial Direct Current Stimulation) contraindications

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: active tDCS; tDCS (transcranial Direct Current Stimulation subjects) is a noninvasive brain stimulation technique that involves the passage of a small electric current through the scalp and skull to modulate brain activity [10]. The study intervention consists of ten 20-minutes sessions of active or sham tDCS. Sessions will be delivered twice daily and separated by at least 2 hours for 5 consecutive weekdays. The electric current will be generated by an electric stimulator (class IIa medical device).	Device: left fronto-temporal transcranial Direct Current Stimulation (tDCS); The study intervention consists of ten 20-minutes sessions of active or sham tDCS. Sessions will be delivered twice daily and separated by at least 2 hours for 5 consecutive weekdays. The electric current will be generated by an electric stimulator (class IIa medical device). During the entire tDCS session, the subject is at "rest", comfortably seated in a chair in a quiet room. A clinician will be present for the entire session duration. The current will be applied via a pair of rubber electrodes (35 cm²) placed on the surface of the scalp. The anode will be placed over the left dorsolateral prefrontal cortex. The cathode will be placed over the left auditory cortex. The stimulation parameters will be set at 2-mA for 20 minutes, with a progressive increase during the first 30-sec and a progressive decrease during the last 30-sec of each session. The impedance of the applied current is monitored by the stimulator during each session.
Sham Comparator: sham tDCS; The sham procedure is developed by the tDCS device manufacturer, which allows using the same tDCS device and the same procedure (i.e., 10 sessions delivered during five consecutive days) for both the active and sham procedures. In the sham condition, the electrodes will be placed in the same positions as in the active group; however, the stimulator will be only active for initial and final ramp up/ramp down periods, in order to mimic the sensation of active stimulation. In addition, brief pulses of 110 μA will be administered every 550 ms in order to control impedance and keep the manipulator blinded to the active or sham condition.	Device: left fronto-temporal transcranial Direct Current Stimulation (tDCS); The study intervention consists of ten 20-minutes sessions of active or sham tDCS. Sessions will be delivered twice daily and separated by at least 2 hours for 5 consecutive weekdays. The electric current will be generated by an electric stimulator (class IIa medical device). During the entire tDCS session, the subject is at "rest", comfortably seated in a chair in a quiet room. A clinician will be present for the entire session duration. The current will be applied via a pair of rubber electrodes (35 cm²) placed on the surface of the scalp. The anode will be placed over the left dorsolateral prefrontal cortex. The cathode will be placed over the left auditory cortex. The stimulation parameters will be set at 2-mA for 20 minutes, with a progressive increase during the first 30-sec and a progressive decrease during the last 30-sec of each session. The impedance of the applied current is monitored by the stimulator during each session.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cognitive response	Number of responders at 1-month after tDCS, defined as the proportion of patients demonstrating a cognitive improvement greater than or equal to Z=0.5 from baseline on the MATRICS Consensus Cognitive Battery total score (MCCB). The MCCB is a gold-standard standardized test battery to assess cognitive functions in patients with schizophrenia. This criterion has been used and validated in both antipsychotic and cognitive remediation trials in schizophrenia.	at 1-month follow-up

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Long term cognitive response	Number of responders at 3-months after tDCS, defined as the proportion of patients demonstrating a cognitive improvement greater than or equal to Z=0.5 from baseline on the MATRICS Consensus Cognitive Battery total score (MCCB). The MCCB is a gold-standard standardized test battery to assess cognitive functions in patients with schizophrenia. This criterion has been used and validated in both antipsychotic and cognitive remediation trials in schizophrenia.	at inclusion; at 3-months follow-up
Cognitive domain response	Changes from baseline to 1-month and 3-months endpoints in each MCCB domains subscores (processing speed, attention/vigilance, working memory, verbal learning, visual learning, problem solving, emotional awareness) and total score.	at inclusion; at 1-month follow-up; at 3-months follow-up
Clinical response 1	Changes from baseline to after tDCS, 1-month and 3-months endpoints in the following symptom measure: • Schizophrenia symptoms will be assessed using the PANSS (Positive and Negative Syndrome Scale) total score.	at inclusion; at 1-week; at 1-month follow-up; at 3-months follow-up
Clinical response 2	Changes from baseline to after tDCS, 1-month and 3-months endpoints in the following symptom measure: • Auditory hallucinations, one of the key symptoms of schizophrenia, will be assessed using the AHRS (Auditory Hallucination Rating Scale)	at inclusion; at 1-week; at 1-month follow-up; at 3-months follow-up
Clinical response 3	Changes from baseline to after tDCS, 1-month and 3-months endpoints in the following symptom measure: • Negative symptoms will be additionally assessed using the Brief Negative Symptom Scale (BNSS).	at inclusion; at 1-week; at 1-month follow-up; at 3-months follow-up
Clinical response 4	Changes from baseline to after tDCS, 1-month and 3-months endpoints in the following symptom measure: • Depressive symptoms will be assessed using the Calgary Depression Scale for Schizophrenia (CDSS) total score.	at inclusion; at 1-week; at 1-month follow-up; at 3-months follow-up
Clinical response 5	Changes from baseline to after tDCS, 1-month and 3-months endpoints in the following symptom measure: • Global symptom severity and treatment response will be assessed using the Clinical Global Impressions Scale (CGI) total score.	at inclusion; at 1-week; at 1-month follow-up; at 3-months follow-up
Clinical response 6	Changes from baseline to after tDCS, 1-month and 3-months endpoints in the following symptom measure: • Subjective experience of negative symptoms will be assessed using the Self-evaluation of Negative Symptoms (SNS) total score	at inclusion; at 1-week; at 1-month follow-up; at 3-months follow-up
Clinical response 7	Changes from baseline to after tDCS, 1-month and 3-months endpoints in the following symptom measure: • Subjective experiences of cognitive impairment will be assessed using the self-rated Subjective Scale To Investigate Cognition in Schizophrenia (SSTICS) total score.	at inclusion; at 1-week; at 1-month follow-up; at 3-months follow-up
Outcome response 1	Changes from baseline to 1-month and 3-months endpoints in the following general outcome measures: • Functional outcome will be assessed using the FROGS (Functional Remission Observatory Group in Schizophrenia) total score	at inclusion; at 1-month follow-up; at 3-months follow-up
Outcome response 2	Changes from baseline to 1-month and 3-months endpoints in the following general outcome measures: • Quality of life will be assessed by the Schizophrenia Quality of Life Questionnaire Short Form (S-QoL 18) total score	at inclusion; at 1-month follow-up; at 3-months follow-up
Tolerance 1	Score after the last tDCS session in the following tolerance measure: • tDCS-AEQ (Adverse Effects Questionnaire)	at 1-week
Tolerance 2	Score after the last tDCS session in the following tolerance measure: • VAMS (Visual Analogue Mood Scale)	at 1-week
Response marker 1	The differences at baseline in the following early auditory processing (EAP) measure between patients with cognitive improvement and patients without cognitive improvement after active tDCS: • correlations (z-scores) between left prefrontal and temporal cortical areas (i.e., areas stimulated with tDCS) measured with resting-state functional Magnetic Resonance Imaging (MRI).	at inclusion
Response marker 2	The differences at baseline in the following early auditory processing (EAP) measure between patients with cognitive improvement and patients without cognitive improvement after active tDCS: • spectral power (dB) in gamma frequency (40-Hz) during specific auditory paradigms (auditory steady-state, oddball, tone-matching) measured with electroencephalography (EEG).	at inclusion
Response marker 3	The differences at baseline in the following early auditory processing (EAP) measure between patients with cognitive improvement and patients without cognitive improvement after active tDCS: • inter-assay coherence (%) in gamma frequency (40-Hz) during specific auditory paradigms (auditory steady-state, oddball, tone-matching) measured with electroencephalography (EEG).	at inclusion
Response marker 4	The differences at baseline in the following early auditory processing (EAP) measure between patients with cognitive improvement and patients without cognitive improvement after active tDCS: • GABA and Glutamate levels (mM) within left prefrontal and temporal cortical areas measured with resting-state Magnetic Resonance Spectroscopy (MRS)	at inclusion
Response marker 5	The differences at baseline in the following early auditory processing (EAP) measure between patients with cognitive improvement and patients without cognitive improvement after active tDCS: • radiotracer binding potential on GABA-A receptors (Binding Potential) within left prefrontal and temporal cortical areas measured with resting-state [11C]flumazenil Positron Emission Tomography MRI (PET-MRI).	at inclusion
Response predictor 1	Changes from baseline to 1-month in the following early auditory processing (EAP) measure between patients with cognitive improvement and patients without cognitive improvement after active tDCS: • correlations (z-scores) between left prefrontal and temporal cortical areas (i.e., areas stimulated with tDCS) measured with resting-state functional Magnetic Resonance Imaging (MRI).	at inclusion; at 1-month follow-up
Response predictor 2	Changes from baseline to 1-month in the following early auditory processing (EAP) measure between patients with cognitive improvement and patients without cognitive improvement after active tDCS: • spectral power (dB) in gamma frequency (40-Hz) during specific auditory paradigms (auditory steady-state, oddball, tone-matching) measured with electroencephalography (EEG).	at inclusion; at 1-month follow-up
Response predictor 3	Changes from baseline to 1-month in the following early auditory processing (EAP) measure between patients with cognitive improvement and patients without cognitive improvement after active tDCS: • inter-assay coherence (%) in gamma frequency (40-Hz) during specific auditory paradigms (auditory steady-state, oddball, tone-matching) measured with electroencephalography (EEG).	at inclusion; at 1-month follow-up
Response predictor 4	Changes from baseline to 1-month in the following early auditory processing (EAP) measure between patients with cognitive improvement and patients without cognitive improvement after active tDCS: • GABA and Glutamate levels (mM) within left prefrontal and temporal cortical areas measured with resting-state Magnetic Resonance Spectroscopy (MRS)	at inclusion; at 1-month follow-up
Response predictor 5	Changes from baseline to 1-month in the following early auditory processing (EAP) measure between patients with cognitive improvement and patients without cognitive improvement after active tDCS: • GABA and Glutamate levels (mM) within left prefrontal and temporal cortical areas measured with resting-state Magnetic Resonance Spectroscopy (MRS)	at inclusion; at 1-month follow-up
Response predictor 6	Changes from baseline 1-month in the following early auditory processing (EAP) measure between patients with cognitive improvement and patients without cognitive improvement after active tDCS: • radiotracer binding potential on GABA-A receptors (Binding Potential) within left prefrontal and temporal cortical areas measured with resting-state [11C]flumazenil Positron Emission Tomography MRI (PET-MRI).	at inclusion; at 1-month follow-up

Collaborators and Investigators

• Sponsor: University Hospital, Grenoble
• Collaborators: Direction Générale de l'Offre de Soins

Study record dates

Study Major Dates

• Study Start (Anticipated): June 1, 2023
• Primary Completion (Anticipated): June 1, 2026
• Study Completion (Anticipated): June 1, 2027

Study Registration Dates

• First Submitted: May 31, 2022
• First Submitted That Met QC Criteria: June 27, 2022
• First Posted (Actual): July 1, 2022

Study Record Updates

• Last Update Posted (Actual): April 4, 2023
• Last Update Submitted That Met QC Criteria: April 3, 2023
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Keywords: tDCS; schizophrenia; clinical trial; cognitive impairment; early auditory processing
• Additional Relevant MeSH Terms: Neurocognitive Disorders; Schizophrenia Spectrum and Other Psychotic Disorders; Cognition Disorders; Schizophrenia; Psychotic Disorders; Mental Disorders; Cognitive Dysfunction
• Other Study ID Numbers: STICOG

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: The data will be available from the principal investigator to other study investigators or scientists upon reasonable request.
• IPD Sharing Time Frame: Paper CRFs will be kept in locked files at the study sites for 15 years. In all study-related documents, participants will appear only in the form of an ID code to ensure confidentiality. All members of the research staff who will have direct access to the data before, during and after the trial will be bound to strict confidentiality rules and will not be allowed to disclose and personal or medical information.
• IPD Sharing Access Criteria: The data will be available from the principal investigator to other study investigators or scientists upon reasonable request.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ANALYTIC_CODE; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No